Cargando…
In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein
BACKGROUND: The CRISPR/Cas9 genome editing system is a powerful and simple gene editing method. The format of the CRISPR components is one of the important factors in targeting efficiency. Compared to plasmid or mRNA (IVTs) format, using the CRISPR/Cas9 system as Cas9–crRNA–tracrRNA RNP format is mo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Avicenna Research Institute
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626505/ https://www.ncbi.nlm.nih.gov/pubmed/31380000 |
_version_ | 1783434581516484608 |
---|---|
author | Mehravar, Maryam Shirazi, Abolfazl Mehrazar, Mohammad Mehdi Nazari, Mahboobeh |
author_facet | Mehravar, Maryam Shirazi, Abolfazl Mehrazar, Mohammad Mehdi Nazari, Mahboobeh |
author_sort | Mehravar, Maryam |
collection | PubMed |
description | BACKGROUND: The CRISPR/Cas9 genome editing system is a powerful and simple gene editing method. The format of the CRISPR components is one of the important factors in targeting efficiency. Compared to plasmid or mRNA (IVTs) format, using the CRISPR/Cas9 system as Cas9–crRNA–tracrRNA RNP format is more efficient and rapid, especially in minimizing some of the pitfalls of CRISPR-mediated gene editing. In addition to efficient in vivo applications of the CRISPR RNP format in a variety of cell types and organisms, another advantage of this approach is usability for in vitro applications in which the crRNAs in the tracrRNA–crRNA structure guides the Mg2+-dependent RNAdirected DNA endonuclease to introduce double-strand breaks at specific sites in DNA. METHODS: Here, Cas9–crRNA–tracrRNA RNP system was used to test the designed crRNAs for in vitro DNA cleavage by Cas9 protein in RAG1, RAG2 and IL2RG genes. RESULTS: The results of cleavage reveal theCas9–crRNA–tracrRNA RNP system is a rapid and efficient way to pre-validate the efficiency of CRISPR cleavage with crRNAs designed for RAG1, RAG2 and IL2RG genes. CONCLUSION: one step in vitro cleavage of DNA by CRISPR/Cas9 ribonucleoprotein complex can be used to pre-validate the functionality and relative efficiency of CRISPR system for targeting genes. |
format | Online Article Text |
id | pubmed-6626505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Avicenna Research Institute |
record_format | MEDLINE/PubMed |
spelling | pubmed-66265052019-08-02 In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein Mehravar, Maryam Shirazi, Abolfazl Mehrazar, Mohammad Mehdi Nazari, Mahboobeh Avicenna J Med Biotechnol Short Communication BACKGROUND: The CRISPR/Cas9 genome editing system is a powerful and simple gene editing method. The format of the CRISPR components is one of the important factors in targeting efficiency. Compared to plasmid or mRNA (IVTs) format, using the CRISPR/Cas9 system as Cas9–crRNA–tracrRNA RNP format is more efficient and rapid, especially in minimizing some of the pitfalls of CRISPR-mediated gene editing. In addition to efficient in vivo applications of the CRISPR RNP format in a variety of cell types and organisms, another advantage of this approach is usability for in vitro applications in which the crRNAs in the tracrRNA–crRNA structure guides the Mg2+-dependent RNAdirected DNA endonuclease to introduce double-strand breaks at specific sites in DNA. METHODS: Here, Cas9–crRNA–tracrRNA RNP system was used to test the designed crRNAs for in vitro DNA cleavage by Cas9 protein in RAG1, RAG2 and IL2RG genes. RESULTS: The results of cleavage reveal theCas9–crRNA–tracrRNA RNP system is a rapid and efficient way to pre-validate the efficiency of CRISPR cleavage with crRNAs designed for RAG1, RAG2 and IL2RG genes. CONCLUSION: one step in vitro cleavage of DNA by CRISPR/Cas9 ribonucleoprotein complex can be used to pre-validate the functionality and relative efficiency of CRISPR system for targeting genes. Avicenna Research Institute 2019 /pmc/articles/PMC6626505/ /pubmed/31380000 Text en Copyright© 2019 Avicenna Research Institute http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Mehravar, Maryam Shirazi, Abolfazl Mehrazar, Mohammad Mehdi Nazari, Mahboobeh In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein |
title | In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein |
title_full | In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein |
title_fullStr | In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein |
title_full_unstemmed | In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein |
title_short | In Vitro Pre-validation of Gene Editing by CRISPR/Cas9 Ribonucleoprotein |
title_sort | in vitro pre-validation of gene editing by crispr/cas9 ribonucleoprotein |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626505/ https://www.ncbi.nlm.nih.gov/pubmed/31380000 |
work_keys_str_mv | AT mehravarmaryam invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein AT shiraziabolfazl invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein AT mehrazarmohammadmehdi invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein AT nazarimahboobeh invitroprevalidationofgeneeditingbycrisprcas9ribonucleoprotein |